Article

Key clinical point: In patients with clinical stage T3/T4a N1-3 M0 gastric cancer, perioperative capecitabine plus oxaliplatin is feasible and associated with a good survival rate.

Major finding: The R0 resection rate was 78.4%. At 3 years, overall survival and relapse-free survival rates were 83.8% (95% CI 72.7%-96.5%) and 73.0% (95% CI 60.0%-88.8%), respectively.

Study details: A phase 2 OGSG 1601 study of 37 patients with clinical stage T3/T4a N1-3 M0 gastric cancer who received perioperative capecitabine plus oxaliplatin therapy.

Disclosures: This study was sponsored by the Osaka Gastrointestinal Cancer Chemotherapy Study Group. The authors declared consulting/advisory relationships, received research funding/honoraria, disclosed being employed or having ownership interests, held intellectual property/inventor/patent rights, or served on scientific advisory boards outside this work.

Source: Matsuyama J et al. Three-year outcomes of a phase II study of perioperative capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601). Oncologist. 2022;27(4):251-e304 (Apr 5). Doi: 10.1093/oncolo/oyab061

Key clinical point: In patients with clinical stage T3/T4a N1-3 M0 gastric cancer, perioperative capecitabine plus oxaliplatin is feasible and associated with a good survival rate.

Major finding: The R0 resection rate was 78.4%. At 3 years, overall survival and relapse-free survival rates were 83.8% (95% CI 72.7%-96.5%) and 73.0% (95% CI 60.0%-88.8%), respectively.

Study details: A phase 2 OGSG 1601 study of 37 patients with clinical stage T3/T4a N1-3 M0 gastric cancer who received perioperative capecitabine plus oxaliplatin therapy.

Disclosures: This study was sponsored by the Osaka Gastrointestinal Cancer Chemotherapy Study Group. The authors declared consulting/advisory relationships, received research funding/honoraria, disclosed being employed or having ownership interests, held intellectual property/inventor/patent rights, or served on scientific advisory boards outside this work.

Source: Matsuyama J et al. Three-year outcomes of a phase II study of perioperative capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601). Oncologist. 2022;27(4):251-e304 (Apr 5). Doi: 10.1093/oncolo/oyab061

Key clinical point: In patients with clinical stage T3/T4a N1-3 M0 gastric cancer, perioperative capecitabine plus oxaliplatin is feasible and associated with a good survival rate.

Major finding: The R0 resection rate was 78.4%. At 3 years, overall survival and relapse-free survival rates were 83.8% (95% CI 72.7%-96.5%) and 73.0% (95% CI 60.0%-88.8%), respectively.

Study details: A phase 2 OGSG 1601 study of 37 patients with clinical stage T3/T4a N1-3 M0 gastric cancer who received perioperative capecitabine plus oxaliplatin therapy.

Disclosures: This study was sponsored by the Osaka Gastrointestinal Cancer Chemotherapy Study Group. The authors declared consulting/advisory relationships, received research funding/honoraria, disclosed being employed or having ownership interests, held intellectual property/inventor/patent rights, or served on scientific advisory boards outside this work.

Source: Matsuyama J et al. Three-year outcomes of a phase II study of perioperative capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601). Oncologist. 2022;27(4):251-e304 (Apr 5). Doi: 10.1093/oncolo/oyab061

Key clinical point: Neoadjuvant treatment with apatinib in combination with oxaliplatin and capecitabine shows good response and a manageable safety profile in patients with locally advanced adenocarcinoma of the stomach or gastroesophageal junction.

Major finding: The objective response rate was 78.1%. Pathological complete response and pathological response was achieved in 6.3% and 34.4% of the patients, respectively. The most common grade 3-4 treatment-emergent adverse events were hypertension (28.1%) and thrombocytopenia (21.9%).

Study details: This article reports a single-center, single-arm, phase 2 study of 32 patients with locally advanced adenocarcinoma of the stomach or gastroesophageal junction undergoing gastrectomy with lymphadenectomy who received neoadjuvant oxaliplatin, capecitabine, and apatinib.

Disclosures: This study was funded by the National Natural Science Foundation of China. The authors declared no competing interests.

Source: Tang Z et al. Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial. BMC Med. 2022;20:107 (Apr 6). Doi: 10.1186/s12916-022-02309-0

Key clinical point: Neoadjuvant treatment with apatinib in combination with oxaliplatin and capecitabine shows good response and a manageable safety profile in patients with locally advanced adenocarcinoma of the stomach or gastroesophageal junction.

Major finding: The objective response rate was 78.1%. Pathological complete response and pathological response was achieved in 6.3% and 34.4% of the patients, respectively. The most common grade 3-4 treatment-emergent adverse events were hypertension (28.1%) and thrombocytopenia (21.9%).

Study details: This article reports a single-center, single-arm, phase 2 study of 32 patients with locally advanced adenocarcinoma of the stomach or gastroesophageal junction undergoing gastrectomy with lymphadenectomy who received neoadjuvant oxaliplatin, capecitabine, and apatinib.

Disclosures: This study was funded by the National Natural Science Foundation of China. The authors declared no competing interests.

Source: Tang Z et al. Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial. BMC Med. 2022;20:107 (Apr 6). Doi: 10.1186/s12916-022-02309-0

Key clinical point: Neoadjuvant treatment with apatinib in combination with oxaliplatin and capecitabine shows good response and a manageable safety profile in patients with locally advanced adenocarcinoma of the stomach or gastroesophageal junction.

Major finding: The objective response rate was 78.1%. Pathological complete response and pathological response was achieved in 6.3% and 34.4% of the patients, respectively. The most common grade 3-4 treatment-emergent adverse events were hypertension (28.1%) and thrombocytopenia (21.9%).

Study details: This article reports a single-center, single-arm, phase 2 study of 32 patients with locally advanced adenocarcinoma of the stomach or gastroesophageal junction undergoing gastrectomy with lymphadenectomy who received neoadjuvant oxaliplatin, capecitabine, and apatinib.

Disclosures: This study was funded by the National Natural Science Foundation of China. The authors declared no competing interests.

Source: Tang Z et al. Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial. BMC Med. 2022;20:107 (Apr 6). Doi: 10.1186/s12916-022-02309-0

Key clinical point: Replacing anthracycline with fractional docetaxel in the epirubicin, oxaliplatin, and capecitabine (EOX) regimen does not improve survival and increases toxicities in chemotherapy-naive patients with human epidermal growth factor receptor 2 (HER2)-negative gastric cancer.

Major finding: At data cutoff of interim analysis, no significant difference was reported between the two treatment groups in progression-free survival (hazard ratio [HR] 0.975; P = .885) and overall survival (HR 1.002; P = .992). Treatment modification (91% vs. 78%; P = .017) and grade ≥3 adverse event rates (51% vs. 43%) were higher in the docetaxel vs. EOX group.

Study details: This study was a randomized, parallel group, open-label phase 3 LEGA trial including 169 chemotherapy-naive patients with HER2-negative gastric cancer who were randomly assigned to receive either EOX or a docetaxel, oxaliplatin, and capecitabine regimen.

Disclosures: No funding source was identified for this work. The authors reported no competing interests.

Source: Rosati G et al. A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: The LEGA trial. Gastric Cancer. 2022 (Mar 30). Doi: 10.1007/s10120-022-01292-y

Key clinical point: Replacing anthracycline with fractional docetaxel in the epirubicin, oxaliplatin, and capecitabine (EOX) regimen does not improve survival and increases toxicities in chemotherapy-naive patients with human epidermal growth factor receptor 2 (HER2)-negative gastric cancer.

Major finding: At data cutoff of interim analysis, no significant difference was reported between the two treatment groups in progression-free survival (hazard ratio [HR] 0.975; P = .885) and overall survival (HR 1.002; P = .992). Treatment modification (91% vs. 78%; P = .017) and grade ≥3 adverse event rates (51% vs. 43%) were higher in the docetaxel vs. EOX group.

Study details: This study was a randomized, parallel group, open-label phase 3 LEGA trial including 169 chemotherapy-naive patients with HER2-negative gastric cancer who were randomly assigned to receive either EOX or a docetaxel, oxaliplatin, and capecitabine regimen.

Disclosures: No funding source was identified for this work. The authors reported no competing interests.

Source: Rosati G et al. A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: The LEGA trial. Gastric Cancer. 2022 (Mar 30). Doi: 10.1007/s10120-022-01292-y

Key clinical point: Replacing anthracycline with fractional docetaxel in the epirubicin, oxaliplatin, and capecitabine (EOX) regimen does not improve survival and increases toxicities in chemotherapy-naive patients with human epidermal growth factor receptor 2 (HER2)-negative gastric cancer.

Major finding: At data cutoff of interim analysis, no significant difference was reported between the two treatment groups in progression-free survival (hazard ratio [HR] 0.975; P = .885) and overall survival (HR 1.002; P = .992). Treatment modification (91% vs. 78%; P = .017) and grade ≥3 adverse event rates (51% vs. 43%) were higher in the docetaxel vs. EOX group.

Study details: This study was a randomized, parallel group, open-label phase 3 LEGA trial including 169 chemotherapy-naive patients with HER2-negative gastric cancer who were randomly assigned to receive either EOX or a docetaxel, oxaliplatin, and capecitabine regimen.

Disclosures: No funding source was identified for this work. The authors reported no competing interests.

Source: Rosati G et al. A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: The LEGA trial. Gastric Cancer. 2022 (Mar 30). Doi: 10.1007/s10120-022-01292-y

Key clinical point: In patients with early-stage gastric cancer, laparoscopic sentinel node navigation surgery (LSNNS) fails to show noninferiority vs. laparoscopic standard gastrectomy (LSG).

Major finding: The median follow-up was 48.1 months. At 3 years, disease-free survival rates were 95.5% and 91.8% in the LSG and LSNNS groups, respectively (difference 3.7%; 95% CI −0.6% to 8.1%). The threshold difference for noninferiority was 5%. No differences were seen in disease-specific survival (P = .59) and overall survival (P = .17) rates at 3 years.

Study details: The prospective, multicenter, randomized controlled phase 3 SENORITA trial included 580 patients with stage IA gastric adenocarcinoma who were randomly assigned to undergo either LSG or LSNNS.

Disclosures: This work was supported by National Cancer Center, Republic of Korea. The authors received honoraria, research funding, or consulting or advisory fees. Dr. WJ Hyung reported being employed at, in a leadership role, owning stocks, and other ownership interests at Hutom.

Source: Kim Y-W et al. Laparoscopic sentinel node navigation surgery for stomach preservation in patients with early gastric cancer: A randomized clinical trial. J Clin Oncol. 2022 (Mar 24). Doi: 10.1200/JCO.21.02242

Key clinical point: In patients with early-stage gastric cancer, laparoscopic sentinel node navigation surgery (LSNNS) fails to show noninferiority vs. laparoscopic standard gastrectomy (LSG).

Major finding: The median follow-up was 48.1 months. At 3 years, disease-free survival rates were 95.5% and 91.8% in the LSG and LSNNS groups, respectively (difference 3.7%; 95% CI −0.6% to 8.1%). The threshold difference for noninferiority was 5%. No differences were seen in disease-specific survival (P = .59) and overall survival (P = .17) rates at 3 years.

Study details: The prospective, multicenter, randomized controlled phase 3 SENORITA trial included 580 patients with stage IA gastric adenocarcinoma who were randomly assigned to undergo either LSG or LSNNS.

Disclosures: This work was supported by National Cancer Center, Republic of Korea. The authors received honoraria, research funding, or consulting or advisory fees. Dr. WJ Hyung reported being employed at, in a leadership role, owning stocks, and other ownership interests at Hutom.

Source: Kim Y-W et al. Laparoscopic sentinel node navigation surgery for stomach preservation in patients with early gastric cancer: A randomized clinical trial. J Clin Oncol. 2022 (Mar 24). Doi: 10.1200/JCO.21.02242

Key clinical point: In patients with early-stage gastric cancer, laparoscopic sentinel node navigation surgery (LSNNS) fails to show noninferiority vs. laparoscopic standard gastrectomy (LSG).

Major finding: The median follow-up was 48.1 months. At 3 years, disease-free survival rates were 95.5% and 91.8% in the LSG and LSNNS groups, respectively (difference 3.7%; 95% CI −0.6% to 8.1%). The threshold difference for noninferiority was 5%. No differences were seen in disease-specific survival (P = .59) and overall survival (P = .17) rates at 3 years.

Study details: The prospective, multicenter, randomized controlled phase 3 SENORITA trial included 580 patients with stage IA gastric adenocarcinoma who were randomly assigned to undergo either LSG or LSNNS.

Disclosures: This work was supported by National Cancer Center, Republic of Korea. The authors received honoraria, research funding, or consulting or advisory fees. Dr. WJ Hyung reported being employed at, in a leadership role, owning stocks, and other ownership interests at Hutom.

Source: Kim Y-W et al. Laparoscopic sentinel node navigation surgery for stomach preservation in patients with early gastric cancer: A randomized clinical trial. J Clin Oncol. 2022 (Mar 24). Doi: 10.1200/JCO.21.02242

Key clinical point: Peficitinib reduced the progression of joint damage compared with placebo in patients with rheumatoid arthritis (RA) who responded inadequately to prior methotrexate.

Major finding: At week 28/early termination, the mean change in overall erosion score and overall joint space narrowing score in patients receiving 100 mg and 150 mg peficitinib vs. placebo was 0.63 ± 2.03 and 0.18 ± 1.10 vs. 1.35 ± 3.01, and 0.99 ± 2.86 and 0.82 ± 2.39 vs. 1.90 ± 3.76, respectively.

Study details: This was a post hoc analysis of phase 3 trial, RAJ4, which included 481 patients with RA who had an inadequate response to methotrexate who were randomly assigned to receive 100 mg or 150 mg peficitinib or placebo, in combination with methotrexate, for 52 weeks.

Disclosures: This study was initiated and supported by Astellas Pharma Inc. Y Tanaka and T Takeuchi reported receiving speaking fees, honoraria, research grants, or consulting fees from various sources. Five authors reported being employees of Astellas Pharma Inc.

Source: Tanaka Y et al. Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4). Mod Rheumatol. 2022 (Mar 10). Doi: 10.1093/mr/roac021

Key clinical point: Peficitinib reduced the progression of joint damage compared with placebo in patients with rheumatoid arthritis (RA) who responded inadequately to prior methotrexate.

Major finding: At week 28/early termination, the mean change in overall erosion score and overall joint space narrowing score in patients receiving 100 mg and 150 mg peficitinib vs. placebo was 0.63 ± 2.03 and 0.18 ± 1.10 vs. 1.35 ± 3.01, and 0.99 ± 2.86 and 0.82 ± 2.39 vs. 1.90 ± 3.76, respectively.

Study details: This was a post hoc analysis of phase 3 trial, RAJ4, which included 481 patients with RA who had an inadequate response to methotrexate who were randomly assigned to receive 100 mg or 150 mg peficitinib or placebo, in combination with methotrexate, for 52 weeks.

Disclosures: This study was initiated and supported by Astellas Pharma Inc. Y Tanaka and T Takeuchi reported receiving speaking fees, honoraria, research grants, or consulting fees from various sources. Five authors reported being employees of Astellas Pharma Inc.

Source: Tanaka Y et al. Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4). Mod Rheumatol. 2022 (Mar 10). Doi: 10.1093/mr/roac021

Key clinical point: Peficitinib reduced the progression of joint damage compared with placebo in patients with rheumatoid arthritis (RA) who responded inadequately to prior methotrexate.

Major finding: At week 28/early termination, the mean change in overall erosion score and overall joint space narrowing score in patients receiving 100 mg and 150 mg peficitinib vs. placebo was 0.63 ± 2.03 and 0.18 ± 1.10 vs. 1.35 ± 3.01, and 0.99 ± 2.86 and 0.82 ± 2.39 vs. 1.90 ± 3.76, respectively.

Study details: This was a post hoc analysis of phase 3 trial, RAJ4, which included 481 patients with RA who had an inadequate response to methotrexate who were randomly assigned to receive 100 mg or 150 mg peficitinib or placebo, in combination with methotrexate, for 52 weeks.

Disclosures: This study was initiated and supported by Astellas Pharma Inc. Y Tanaka and T Takeuchi reported receiving speaking fees, honoraria, research grants, or consulting fees from various sources. Five authors reported being employees of Astellas Pharma Inc.

Source: Tanaka Y et al. Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4). Mod Rheumatol. 2022 (Mar 10). Doi: 10.1093/mr/roac021

Key clinical point: Patients with seropositive rheumatoid arthritis (RA) treated with tumor necrosis factor inhibitors (TNFi) were at higher risk of developing nontuberculous mycobacterium (NTM) infection in mycobacterium tuberculosis (MTB) endemic areas.

Major finding: Patients with seropositive RA from an MTB endemic area, who were treated with vs. without TNFi were at a significantly higher risk for NTM infection (adjusted hazard ratio [aHR] 1.751; 95% CI 1.105-2.774), with females (aHR 2.108), patients aged 50-65 years (aHR 2.018), and patients without comorbidities (aHR 1.742; all P < .001) at higher risk of developing NTM infection after TNFi treatment.

Study details: This was a retrospective, population-based longitudinal cohort study including patients with seropositive RA. Of these, 1089 patients treated with TNFI were propensity-matched with 4356 untreated patients.

Disclosures: The study was supported by the research fund of Hanyang University, Republic of Korea. The authors declared no conflicts of interest.

Source: Park DW et al. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials. Sci Rep. 2022;12:4003 (Mar 7). Doi: 10.1038/s41598-022-07968-w

Key clinical point: Patients with seropositive rheumatoid arthritis (RA) treated with tumor necrosis factor inhibitors (TNFi) were at higher risk of developing nontuberculous mycobacterium (NTM) infection in mycobacterium tuberculosis (MTB) endemic areas.

Major finding: Patients with seropositive RA from an MTB endemic area, who were treated with vs. without TNFi were at a significantly higher risk for NTM infection (adjusted hazard ratio [aHR] 1.751; 95% CI 1.105-2.774), with females (aHR 2.108), patients aged 50-65 years (aHR 2.018), and patients without comorbidities (aHR 1.742; all P < .001) at higher risk of developing NTM infection after TNFi treatment.

Study details: This was a retrospective, population-based longitudinal cohort study including patients with seropositive RA. Of these, 1089 patients treated with TNFI were propensity-matched with 4356 untreated patients.

Disclosures: The study was supported by the research fund of Hanyang University, Republic of Korea. The authors declared no conflicts of interest.

Source: Park DW et al. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials. Sci Rep. 2022;12:4003 (Mar 7). Doi: 10.1038/s41598-022-07968-w

Key clinical point: Patients with seropositive rheumatoid arthritis (RA) treated with tumor necrosis factor inhibitors (TNFi) were at higher risk of developing nontuberculous mycobacterium (NTM) infection in mycobacterium tuberculosis (MTB) endemic areas.

Major finding: Patients with seropositive RA from an MTB endemic area, who were treated with vs. without TNFi were at a significantly higher risk for NTM infection (adjusted hazard ratio [aHR] 1.751; 95% CI 1.105-2.774), with females (aHR 2.108), patients aged 50-65 years (aHR 2.018), and patients without comorbidities (aHR 1.742; all P < .001) at higher risk of developing NTM infection after TNFi treatment.

Study details: This was a retrospective, population-based longitudinal cohort study including patients with seropositive RA. Of these, 1089 patients treated with TNFI were propensity-matched with 4356 untreated patients.

Disclosures: The study was supported by the research fund of Hanyang University, Republic of Korea. The authors declared no conflicts of interest.

Source: Park DW et al. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials. Sci Rep. 2022;12:4003 (Mar 7). Doi: 10.1038/s41598-022-07968-w

Key clinical point: Patients with rheumatoid arthritis (RA) showed greater clinically meaningful improvements in fatigue, sleep, and health-related quality of life (HRQoL) with tofacitinib vs. placebo over 6 months, with improvements sustained up to 12 months.

Major finding: The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) total score, Medical Outcomes Study Sleep scale (MOS-SS) Sleep Problems Index I and II scores, and Short Form-36 Health Survey (Physical/Mental Component Summary) score improved significantly with both  5 mg or 10 mg tofacitinib doses vs. placebo at months 1, 3, and 6 (all P < .05). Improvement in FACIT-F and MOS-SS scores were significantly better with 10 mg tofacitinib vs. adalimumab at 6 and 12 months (all P < .05).

Study details: This was a post hoc analysis of three phase 3 trials including 2265 patients with RA who received tofacitinib, placebo, or adalimumab.

Disclosures: This study was sponsored by Pfizer Inc. C Murray, D Gruben, and DA Gold declared being employees and stockholders of Pfizer. Some authors declared being on steering committees, boards of directors, or speakers’ bureaus or receiving consulting fees or research grants from various sources, including Pfizer.

Source: Bartlett SJ et al. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from phase 3 trials. Arthritis Res Ther. 2022;24:83 (Apr 5). Doi: 10.1186/s13075-022-02724-x

Key clinical point: Patients with rheumatoid arthritis (RA) showed greater clinically meaningful improvements in fatigue, sleep, and health-related quality of life (HRQoL) with tofacitinib vs. placebo over 6 months, with improvements sustained up to 12 months.

Major finding: The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) total score, Medical Outcomes Study Sleep scale (MOS-SS) Sleep Problems Index I and II scores, and Short Form-36 Health Survey (Physical/Mental Component Summary) score improved significantly with both  5 mg or 10 mg tofacitinib doses vs. placebo at months 1, 3, and 6 (all P < .05). Improvement in FACIT-F and MOS-SS scores were significantly better with 10 mg tofacitinib vs. adalimumab at 6 and 12 months (all P < .05).

Study details: This was a post hoc analysis of three phase 3 trials including 2265 patients with RA who received tofacitinib, placebo, or adalimumab.

Disclosures: This study was sponsored by Pfizer Inc. C Murray, D Gruben, and DA Gold declared being employees and stockholders of Pfizer. Some authors declared being on steering committees, boards of directors, or speakers’ bureaus or receiving consulting fees or research grants from various sources, including Pfizer.

Source: Bartlett SJ et al. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from phase 3 trials. Arthritis Res Ther. 2022;24:83 (Apr 5). Doi: 10.1186/s13075-022-02724-x

Key clinical point: Patients with rheumatoid arthritis (RA) showed greater clinically meaningful improvements in fatigue, sleep, and health-related quality of life (HRQoL) with tofacitinib vs. placebo over 6 months, with improvements sustained up to 12 months.

Major finding: The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) total score, Medical Outcomes Study Sleep scale (MOS-SS) Sleep Problems Index I and II scores, and Short Form-36 Health Survey (Physical/Mental Component Summary) score improved significantly with both  5 mg or 10 mg tofacitinib doses vs. placebo at months 1, 3, and 6 (all P < .05). Improvement in FACIT-F and MOS-SS scores were significantly better with 10 mg tofacitinib vs. adalimumab at 6 and 12 months (all P < .05).

Study details: This was a post hoc analysis of three phase 3 trials including 2265 patients with RA who received tofacitinib, placebo, or adalimumab.

Disclosures: This study was sponsored by Pfizer Inc. C Murray, D Gruben, and DA Gold declared being employees and stockholders of Pfizer. Some authors declared being on steering committees, boards of directors, or speakers’ bureaus or receiving consulting fees or research grants from various sources, including Pfizer.

Source: Bartlett SJ et al. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from phase 3 trials. Arthritis Res Ther. 2022;24:83 (Apr 5). Doi: 10.1186/s13075-022-02724-x

Key clinical point: Children of mothers, but not fathers, with rheumatoid arthritis (RA) were predisposed to the risk of developing multiple mental disorders.

Major finding: Children of mothers with RA had a significantly higher risk for autism spectrum disorders (odds ratio [OR] 1.49; 95% CI 1.01-2.20), bipolar disorder (OR 1.47; 95% CI 1.20-1.81), attention-deficit/hyperactivity disorder (OR 1.37; 95% CI 1.17-1.60), and major depressive disorder (OR 1.20; 95% CI 1.05-1.37), with no risk for these disorders observed in children of fathers with RA.

Study details: This was a retrospective cohort study including 23,981 RA-parent-child pairs and age-/sex-matched 239,810 non-RA-parent-child pairs.

Disclosures: This study received research grants from Taipei Veterans General Hospital, Yen

Tjing Ling Medical Foundation, and the Ministry of Science and Technology, Taiwan. The authors declared no conflicts of interest.

Source: Chiu HJ et al. A nationwide study of the risks of major mental disorders among the offspring of parents with rheumatoid arthritis. Sci Rep. 2022;12:4962 (Mar 23). Doi: 10.1038/s41598-022-08834-5

Key clinical point: Children of mothers, but not fathers, with rheumatoid arthritis (RA) were predisposed to the risk of developing multiple mental disorders.

Major finding: Children of mothers with RA had a significantly higher risk for autism spectrum disorders (odds ratio [OR] 1.49; 95% CI 1.01-2.20), bipolar disorder (OR 1.47; 95% CI 1.20-1.81), attention-deficit/hyperactivity disorder (OR 1.37; 95% CI 1.17-1.60), and major depressive disorder (OR 1.20; 95% CI 1.05-1.37), with no risk for these disorders observed in children of fathers with RA.

Study details: This was a retrospective cohort study including 23,981 RA-parent-child pairs and age-/sex-matched 239,810 non-RA-parent-child pairs.

Disclosures: This study received research grants from Taipei Veterans General Hospital, Yen

Tjing Ling Medical Foundation, and the Ministry of Science and Technology, Taiwan. The authors declared no conflicts of interest.

Source: Chiu HJ et al. A nationwide study of the risks of major mental disorders among the offspring of parents with rheumatoid arthritis. Sci Rep. 2022;12:4962 (Mar 23). Doi: 10.1038/s41598-022-08834-5

Key clinical point: Children of mothers, but not fathers, with rheumatoid arthritis (RA) were predisposed to the risk of developing multiple mental disorders.

Major finding: Children of mothers with RA had a significantly higher risk for autism spectrum disorders (odds ratio [OR] 1.49; 95% CI 1.01-2.20), bipolar disorder (OR 1.47; 95% CI 1.20-1.81), attention-deficit/hyperactivity disorder (OR 1.37; 95% CI 1.17-1.60), and major depressive disorder (OR 1.20; 95% CI 1.05-1.37), with no risk for these disorders observed in children of fathers with RA.

Study details: This was a retrospective cohort study including 23,981 RA-parent-child pairs and age-/sex-matched 239,810 non-RA-parent-child pairs.

Disclosures: This study received research grants from Taipei Veterans General Hospital, Yen

Tjing Ling Medical Foundation, and the Ministry of Science and Technology, Taiwan. The authors declared no conflicts of interest.

Source: Chiu HJ et al. A nationwide study of the risks of major mental disorders among the offspring of parents with rheumatoid arthritis. Sci Rep. 2022;12:4962 (Mar 23). Doi: 10.1038/s41598-022-08834-5

Key clinical point: Patients with seropositive rheumatoid arthritis (RA) were at a higher risk of developing primary open-angle glaucoma (POAG) compared with matched control participants, with risk being evident within 2 years after RA diagnosis and among patients aged ≥75 years.

Major finding: Compared with matched control participants, patients with incident RA were 1.44 times more likely to develop POAG (hazard ratio [HR] 1.44; 95% CI 1.13-1.84), which was predominantly observed within 2 years of RA diagnosis (HR 1.83; 95% CI 1.28-2.61) and in patients aged ≥75 years (HR 2.12;95% CI 1.34-3.35).

Study details: This was a retrospective, nationwide cohort study including 2049 patients with seropositive RA who were propensity score-matched with 8196 control participants without RA.

Disclosures: This study was partly supported by the publication fee from the Graduate School of Public Health, Yonsei University. No conflicts of interest were declared.

Source: Kim SH et al. Development of open-angle glaucoma in adults with seropositive rheumatoid arthritis in Korea. JAMA Netw Open. 2022;5(3):e223345 (Mar 21). Doi:  10.1001/jamanetworkopen.2022.3345

Key clinical point: Patients with seropositive rheumatoid arthritis (RA) were at a higher risk of developing primary open-angle glaucoma (POAG) compared with matched control participants, with risk being evident within 2 years after RA diagnosis and among patients aged ≥75 years.

Major finding: Compared with matched control participants, patients with incident RA were 1.44 times more likely to develop POAG (hazard ratio [HR] 1.44; 95% CI 1.13-1.84), which was predominantly observed within 2 years of RA diagnosis (HR 1.83; 95% CI 1.28-2.61) and in patients aged ≥75 years (HR 2.12;95% CI 1.34-3.35).

Study details: This was a retrospective, nationwide cohort study including 2049 patients with seropositive RA who were propensity score-matched with 8196 control participants without RA.

Disclosures: This study was partly supported by the publication fee from the Graduate School of Public Health, Yonsei University. No conflicts of interest were declared.

Source: Kim SH et al. Development of open-angle glaucoma in adults with seropositive rheumatoid arthritis in Korea. JAMA Netw Open. 2022;5(3):e223345 (Mar 21). Doi:  10.1001/jamanetworkopen.2022.3345

Key clinical point: Patients with seropositive rheumatoid arthritis (RA) were at a higher risk of developing primary open-angle glaucoma (POAG) compared with matched control participants, with risk being evident within 2 years after RA diagnosis and among patients aged ≥75 years.

Major finding: Compared with matched control participants, patients with incident RA were 1.44 times more likely to develop POAG (hazard ratio [HR] 1.44; 95% CI 1.13-1.84), which was predominantly observed within 2 years of RA diagnosis (HR 1.83; 95% CI 1.28-2.61) and in patients aged ≥75 years (HR 2.12;95% CI 1.34-3.35).

Study details: This was a retrospective, nationwide cohort study including 2049 patients with seropositive RA who were propensity score-matched with 8196 control participants without RA.

Disclosures: This study was partly supported by the publication fee from the Graduate School of Public Health, Yonsei University. No conflicts of interest were declared.

Source: Kim SH et al. Development of open-angle glaucoma in adults with seropositive rheumatoid arthritis in Korea. JAMA Netw Open. 2022;5(3):e223345 (Mar 21). Doi:  10.1001/jamanetworkopen.2022.3345

Key clinical point: Some patients with rheumatoid arthritis (RA) had excess disability despite low inflammation level. This persisted over 8-10 years after onset, with age, pain, and depression being significant predictors of disability, independent of inflammation.

Major finding: Nearly 30%-45% of patients with RA persistently showed excess disability over 8-10 years of follow-up, independent of their inflammation status. Patients who were older (odds ratio [OR] 1.05; 95% CI 1.02-1.09) or had higher pain (OR 1.48; 95% CI 1.23-1.78) or depression (OR 1.40; 95% CI 1.01-1.94) were more likely to have higher vs. lower disability trajectory, irrespective of their inflammation level.

Study details: Findings are from an analysis of three cohort studies including 2500 patients with RA and <24 months symptom duration who were followed-up for 8-10 years.

Disclosures: This study was supported by the UK Medical Research Council, Versus Arthritis, UK National Institute for Health Care and Research (NIHR) Manchester Biomedical Research Centre, and NIHR Nottingham Biomedical Research Centre. The authors declared no competing interests directly relevant to this manuscript.

Source: Gwinnutt JM et al. Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis. Rheumatology (Oxford). 2022 (Mar 11). Doi: 10.1093/rheumatology/keac137

Key clinical point: Some patients with rheumatoid arthritis (RA) had excess disability despite low inflammation level. This persisted over 8-10 years after onset, with age, pain, and depression being significant predictors of disability, independent of inflammation.

Major finding: Nearly 30%-45% of patients with RA persistently showed excess disability over 8-10 years of follow-up, independent of their inflammation status. Patients who were older (odds ratio [OR] 1.05; 95% CI 1.02-1.09) or had higher pain (OR 1.48; 95% CI 1.23-1.78) or depression (OR 1.40; 95% CI 1.01-1.94) were more likely to have higher vs. lower disability trajectory, irrespective of their inflammation level.

Study details: Findings are from an analysis of three cohort studies including 2500 patients with RA and <24 months symptom duration who were followed-up for 8-10 years.

Disclosures: This study was supported by the UK Medical Research Council, Versus Arthritis, UK National Institute for Health Care and Research (NIHR) Manchester Biomedical Research Centre, and NIHR Nottingham Biomedical Research Centre. The authors declared no competing interests directly relevant to this manuscript.

Source: Gwinnutt JM et al. Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis. Rheumatology (Oxford). 2022 (Mar 11). Doi: 10.1093/rheumatology/keac137

Key clinical point: Some patients with rheumatoid arthritis (RA) had excess disability despite low inflammation level. This persisted over 8-10 years after onset, with age, pain, and depression being significant predictors of disability, independent of inflammation.

Major finding: Nearly 30%-45% of patients with RA persistently showed excess disability over 8-10 years of follow-up, independent of their inflammation status. Patients who were older (odds ratio [OR] 1.05; 95% CI 1.02-1.09) or had higher pain (OR 1.48; 95% CI 1.23-1.78) or depression (OR 1.40; 95% CI 1.01-1.94) were more likely to have higher vs. lower disability trajectory, irrespective of their inflammation level.

Study details: Findings are from an analysis of three cohort studies including 2500 patients with RA and <24 months symptom duration who were followed-up for 8-10 years.

Disclosures: This study was supported by the UK Medical Research Council, Versus Arthritis, UK National Institute for Health Care and Research (NIHR) Manchester Biomedical Research Centre, and NIHR Nottingham Biomedical Research Centre. The authors declared no competing interests directly relevant to this manuscript.

Source: Gwinnutt JM et al. Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis. Rheumatology (Oxford). 2022 (Mar 11). Doi: 10.1093/rheumatology/keac137